Simultaneous protein expression and modification: An efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system

Journal of Biomolecular Techniques

Volumn 21, Issue 1, 2010, Pages 9-17

  Erdmann, Dirk ^a   Zimmermann, Catherine ^a   Fontana, Patrizia ^a   Hau, Jean Christophe ^a   De Pover, Alain ^a   Chène, Patrick ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biotin; Phosphatase; Phosphorylation

Indexed keywords

BIOTIN; BIOTIN LIGASE; INSULIN RECEPTOR; LIGASE; PHOSPHATASE; PHOSPHATASE YOPH; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN LIGASE BIRA; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; BINDING SITE; BIOTINYLATION; CATALYSIS; CYTOPLASM; ENZYME ACTIVATION; ENZYME ASSAY; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSECT CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VIRUS INFECTION;

ANIMALS; BACULOVIRIDAE; BIOTINYLATION; BLOTTING, WESTERN; CELL EXTRACTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MASS SPECTROMETRY; MOLECULAR BIOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; STAINING AND LABELING;

HEXAPODA;

EID: 77953652923     PISSN: 15240215     EISSN: 19434731     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934. (Pubitemid 35425239)
2. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2: 296-313. (Pubitemid 37361688)
3. Cohen P. Protein kinases - the major drug targets of the twenty- first century? Nat Rev Drug Discov 2002; 1: 309-315. (Pubitemid 37361447)
4. Chene P. Challenges in design of biochemical assays for the identification ofsmall molecules to target multiple conformations of protein kinases. Drug Discov Today 2008; 13: 522-529.
5. Liao JJ, Andrews RC. Targeting protein multiple conformations: A structure-based strategy for kinase drug design. Curr Top Med Chem 2007; 7: 1394-1407. (Pubitemid 47471237)
6. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl- dependent cell proliferation. Nat Chem Biol 2006; 2: 95-102.
7. Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007; 12: 622-633.
8. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39.
9. Phospho.ELM Database Version 8.2, April 2009. http://phospho.elm.eu.org/ 2009.
10. Peterson JE, Kulik G, Jelinek T, Reuter CW, Shannon JA, Weber MJ. Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation bysrc. J Biol Chem 1996; 271: 31562-31571. (Pubitemid 26408616)
11. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1-4.
12. Jiang Y, Chan JL, Zong CS, Wang LH. Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem 1996; 271: 160-167. (Pubitemid 3027736)
13. Ouwens DM, van der Zon GC, Pronk GJ, et al. A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein 2 (Grb2) complex and p21ras-GTP without detectable interaction of insulin receptor substrate 1 (IRS1) with Grb2. Evidence for IRS1-independent p21ras-GTP formation. JBiol Chem 1994; 269: 33116-33122.
14. Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation ofthe insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001; 8: 1058-1063. (Pubitemid 33101627)
15. Du P, Loulakis P, Luo C, et al. Phosphorylation ofserine residues in histidine-tag sequences attached to recombinant protein kinases: A cause of heterogeneity in mass and complications in function. Protein Expr Purif 2005; 44: 121-129.
16. Haacke A, Fendrich G, Ramage P, Geiser, M. Chaperone Over- expression in Escherichia coli: Apparent increased yields ofsoluble recombinant protein kinases are due mainly to soluble aggregates. Protein Expr Purif 2009; 64: 185-193.
17. Elling RA, Tangonan BT, Penny DM, et al. Mouse Aurora A: expression in Escherichia coli and purification. Protein Expr Purif 2007; 54: 139-146.
18. Wang L, Foster M, Zhang Y, et al. High yield expression of non-phosphorylated protein tyrosine kinases in insect cells. Protein Expr Purif 2008; 61: 204-211.
19. Smith CK, CarrD, MayhoodTW, Jin W, Gray K, Windsor WT. Expression and purification of phosphorylated and non-phosphor- ylated human MEK1. Protein Expr Purif2007; 52: 446-456.
20. Høyer-Hansen G, Hamers MJ, Pedersen AN, et al. Loss of ELISA specificity due to biotinylation of monoclonal antibodies. J Immunol Methods 2000; 235: 91-99.
21. Santala V, Lamminmaki U. Production of a biotinylated single- chain antibody fragment in the cytoplasm of Escherichia coli. J Immunol Methods 2004; 284: 165-175.
22. Chapman-Smith A, Cronan Jr. JE. In vivo enzymatic protein biotinylation. Biomol Eng 1999; 16: 119-125.
23. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitu- mor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
24. Schatz PJ. Use ofpeptide libraries to map the substrate specificity of a peptide-modifying enzyme: A 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (NY) 1993; 11: 1138-1143.
25. Wasilko DJ, Lee SE. TIPS: Titerless Infected-Cells Preservation and Scale-up. Bio Process J 2006; 5: 29-32.
26. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 1996; 236: 302-308.
27. Chene P. Study of the selectivity of type I insulin-like growth factor receptor (IGF1R) inhibitors, in press, Open Enz Lnh J.
28. Bliska JB, Clemens JC, Dixon JE, Falkow S. The Yersinia tyrosine phosphatase: Specificity of a bacterial virulence determinant for phosphoproteins in the J 774A.1 macrophage. J Exp Med 1992; 176: 1625-1630.
29. Guan KL, Dixon JE. Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science 1990; 249: 553-556. (Pubitemid 120031646)
30. Zhang ZY, Clemens JC, Schubert HL, et al. Expression, purification, and physicochemical characterization of a recombinant Yersinia protein tyrosine phosphatase. J Biol Chem 1992; 267: 23759-23766.
31. Seeliger MA, Young M, Henderson MN, et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 2005; 14: 3135-3139. (Pubitemid 41770154)
32. Cronan Jr. J.E. Biotination of proteins in vivo. A post-transla- tional modification to label, purify, and study proteins. J Biol Chem 1990; 265: 10327-10333. (Pubitemid 20212756)
33. Chapman-Smith A, Cronan Jr. JE. The enzymatic biotinylation of proteins: A post-translational modification of exceptional specificity. Trends Biochem Sci 1999; 24: 359-363. (Pubitemid 29421812)
34. Smith, PA, Tripp BC, DiBlasio-Smith EA, Lu Z, LaVallie ER, McCoy JM. A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli. Nucleic Acids Res 1998; 26: 1414-1420. (Pubitemid 28291615)
35. YangJ, Jaramillo A, Shi R, KwokWW, MohanakumarT. In vivo biotinylation of the major histocompatibility complex (MHC) class Il/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers. Hum Immunol 2004; 65: 692-699. (Pubitemid 39061165)